Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Hot Drugs 2004
  • Published:

Metabolic and other disorders

Nature Reviews Drug Discovery volume 3, pages S34–S36 (2004)Cite this article

Brand name: Somavert Company: Pfizer Approved: 25 March 2003 Condition treated: acromegaly Action: growth-hormone receptor antagonist CAS number: 218620-50-9

Acromegaly is a rare endocrine disorder caused by hypersecretion of growth hormone (GH), usually from a pituitary somatotroph adenoma1. Prolonged elevation of the levels of GH and insulin-like growth factor-1 (IGF1), which is generated by the action of GH on its receptor, result in the many signs and symptoms of the disease, such as soft-tissue swelling, arthralgia, perspiration, headache and fatigue. Patients with acromegaly can develop diabetes mellitus and hypertension, and have a reduced life expectancy if untreated.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Paisley, A. N. & Trainer, P. J. Medical treatment in acromegaly. Curr. Opin. Pharmacol. 3, 672–677 (2003).

    Article  CAS  Google Scholar 

  2. Parkinson, C. et al. Pegvisomant in the treatment of acromegaly. Adv. Drug Deliv. Rev. 55, 1303–1314 (2003).

    Article  CAS  Google Scholar 

  3. FDA Drug Approvals List [online] (cited 19 April 2004) <http://www.fda.gov/cder/foi/label/2003/21106_somavert_lbl.pdf> (2003).

  4. Trainer, P. J. et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med. 342 1171–1177 (2000).

    Article  CAS  Google Scholar 

  5. Van der Lely, A. J. et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358, 1754–1759 (2001).

    Article  CAS  Google Scholar 

  6. Desnick, R. J. & Schuchman, E. H. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nature Rev. Genet. 3, 954–966 (2002).

    Article  CAS  Google Scholar 

  7. Eng, C. M. et al. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N. Engl. J. Med. 345, 9–16 (2001).

    Article  CAS  Google Scholar 

  8. FDA Drug Approvals List [online] (cited 19 April 2004) <http://www.fda.gov/cder/foi/label/2003/agalgen042403LB.pdf> (2003).

  9. Kakkis, E. D. et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 344, 182–188 (2001).

    Article  CAS  Google Scholar 

  10. FDA Drug Approvals List [online] (cited 19 April 2004) <http://www.fda.gov/cder/foi/label/2003/larobio043003LB.pdf> (2003).

  11. Goltzman, D. Discoveries, drugs and skeletal disorders. Nature Rev. Drug Disc. 1, 784–796 (2002).

    Article  CAS  Google Scholar 

  12. FDA Drug Approvals List [online] (cited 19 April 2004) <http://www.fda.gov/cder/foi/label/2003/21455_boniva_lbl.pdf> (2003).

  13. Muhlbauer, R. C. et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J. Bone Miner. Res. 6, 1003–1011 (1991).

    Article  CAS  Google Scholar 

  14. Cooper, K. L. et al. α-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. Drugs 57, 9–17 (1999).

    Article  CAS  Google Scholar 

  15. Roehrborn, C. G. Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective α-blocker. Urology 58, (S6A) 55–64 (2001).

    Article  CAS  Google Scholar 

  16. FDA Drug Approvals List [online] (cited 19 April 2004) <http://www.fda.gov/cder/foi/label/2003/21287_uroxatral_lbl.pdf> (2003).

  17. Beutler, E. & Grabowski, G. A. Gaucher disease. Metabolic and Molecular Bases of Inherited Disease Vol. 2 (eds Scriver, C. R. et al.) 3635–3668 (McGraw-Hill, New York, 2001).

    Google Scholar 

  18. Cox, T. M. et al. Advisory Council to the European Working Group on Gaucher Disease. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type 1 (non-neuronopathic) Gaucher disease: a position statement. J. Inherit. Metab. Dis. 26, 513–526 (2003).

    Article  CAS  Google Scholar 

  19. FDA Drug Approvals List [online] (cited 19 April 2004) <http://www.fda.gov/cder/foi/label/2003/21348_zavesca_lbl.pdf> (2003).

  20. FDA News [online] (cited 19 April 2004) <http://www.fda.gov/bbs/topics/NEWS/2003/NEW00950.html> (2003).

  21. FDA Drug Approvals List [online] (cited 19 April 2004) <http://www.fda.gov/cder/foi/label/2003/021626lbl.pdf> (2003).

Download references

Additional information

Authorship This section was authored by Cari Berg, Regina Eum and Peter Kirkpatrick. Cari Berg and Regina Eum are at Decision Resources Inc., 260 Charles Street, Waltham, Massachusetts 02453, USA. Peter Kirkpatrick is at Nature Reviews Drug Discovery.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Metabolic and other disorders. Nat Rev Drug Discov 3 (Suppl 7), S34–S36 (2004). https://doi.org/10.1038/nrd1410

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1410

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing